title: [Conservative treatment of high-risk (T1G3) transitional carcinoma].
abstract: OBJECTIVE
  This study evaluates the outcome of patients (pts) with primary T1G3 bladder cancer treated by transurethral resection (TUR) alone or followed by intravesical prophylaxis (BCG/Doxorubicin). Cistectomy was considered at disease progression.
  
  
  METHODS
  Between 1/89 and 5/95 thirty-one pts with primary T1G3 bladder cancer were treated by TUR, in 24 followed by intravesical prophylaxis (13 with BCG, 11 with Doxorubicin). 7 pts had only TUR.
  
  
  RESULTS
  At 42 months median follow up 45.2% pts (14/31) are disease free. The recurrence rate was 25.8% (8/31) and progression of disease was seen in 29.0% (9/31); mortality rate was 22.6% (7/31). In 13/31 pts treated by TUR + BCG 53.8% pts (7/13) are disease free. The recurrance rate was 23.1% (3/13) and progression of disease was seen in 23.1% (3/13) of cases; mortality rate was 23.1% (3/13). In 11/31 pts treated by TUR+Doxorubicin 54.5% pts (6/11) are disease free. The recurrance rate was 18.2% (2/11), progression of disease was seen in 27.3% (3/11) of cases of mortality rate of 9.1% (1/11). In 7/31 pts treated by TUR alone 14.3% pts (1/7) are disease free. The recurrance rate was 42.9% (3/7) and progression of disease was seen in 42.9% (3/7) of cases and mortality rate of 42.9% (3/7). Cistectomy was considered in 4 pts (3 for disease progression and 1 because of no disease free interval). The other pts with progression were not treated surgically because of their poor performance status.
  
  
  CONCLUSIONS
  At a 42 months median follow up 77.4% pts (24/31) are alive (83.3% pts treated by TUR+intravesical prophylaxis). 64.5% pts (20/31) still have their bladder (66.6% pts treated by TUR+intravesical prophylaxis (16/24). We did not find a significative difference between prophylaxis with immunotherapy or chemotherapy. In conclusion we believe that the conservative management of high risk bladder transitional cell carcinoma T1G3 is feasible and allow us to plan cistectomy only in pts with progression or recurrance with no free interval without losing survival.
authors.affiliation: Divisione di Urologia, Desio, Milano.
authors.forename: F
authors.initials: F
authors.lastname: Catanzaro
authors.forename: F
authors.initials: F
authors.lastname: Torelli
authors.forename: M
authors.initials: M
authors.lastname: Catanzaro
authors.forename: F
authors.initials: F
authors.lastname: Cappellano
authors.forename: M
authors.initials: M
authors.lastname: Pizzoccaro
authors.forename: M
authors.initials: M
authors.lastname: Baruffi
authors.forename: D
authors.initials: D
authors.lastname: Sironi
authors.forename: G L
authors.initials: GL
authors.lastname: Pozzoli
mesh_terms: D000283:Administration, Intravesical; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D001500:BCG Vaccine / Q000008:administration & dosage; D002295:Carcinoma, Transitional Cell / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D003131:Combined Modality Therapy; D015653:Cystectomy; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D007167:Immunotherapy; D009364:Neoplasm Recurrence, Local; D011379:Prognosis; D012307:Risk Factors; D013997:Time Factors; D001743:Urinary Bladder / Q000473:pathology; D001749:Urinary Bladder Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*
chemical_list: D000903:Antibiotics, Antineoplastic; D001500:BCG Vaccine; D004317:Doxorubicin
vernacular_title: Il trattamento conservativo nel carcinoma transizionale ad alto rischio (T1G3).